We are close...
Huge tailwinds driving this company and their products.
Great investor sentiment surrounding MedTech, particularly in home-based therapies and precision-based personal care.
Clear and transparent strategy / revenue model communicated to market, with gross product margin of 68%...
No fluff management, all killer and no filler.
Azure Capita behind the deal.
Italian distribution agreement already signed with an obligation to purchase a minimum of 8,700 units up to July 2019. This agreement is almost to the value of market-cap on listing.
Big juicy markets to penetrate - http://www.neurotechindustry.org/access-to-capital
"In 2013, the 800 companies involved in the global neurotech industry generated $160 billion in revenue"
Not much to fault at this stage, add the ridiculously tiny market cap into the mix and you have a potential star.
Code available for discussion, page-38
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
